BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND ESR1, ESR, 2099, ENSG00000091831, RP1-130E4_1, NR3A1, ESRA, DKFZp686N23123, ER, Era
39090 results:

  • 1. Analysis of BRCA1 germline variants (exons 5, 11 and 20) in breast cancer families from Libya.
    Elmaihub ES; Alhudiri I; Ramadan AM; Eljilani M; Elzagheid A; Elfagi F; Hassen E
    Libyan J Med; 2024 Dec; 19(1):2356906. PubMed ID: 38785139
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Paeoniflorigenone inhibits ovarian cancer metastasis through targeting the MUC1/Wnt/β‑catenin pathway.
    Liu Q; Jiang L; Zhao Y; Su F; Li J; Tian X; Liu W; Jiang X; Xu Y; Tao F
    Int J Mol Med; 2024 Jul; 54(1):. PubMed ID: 38785138
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Hybrid chain reaction and selective recognition-based homogeneous dual-fluorescence analysis of circulating tumor cells in clinical ovarian cancer samples.
    Hu Q; Tang D; Li M; Liang X; Zhou J; Meng Y; Wei Y; Yan S; Lin R; Niu X; Zhang L
    Anal Chim Acta; 2023 Nov; 1281():341877. PubMed ID: 38783734
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Causal relationship between thyroid dysfunction and ovarian cancer: a two-sample Mendelian randomization study.
    Wang T; Wang X; Wu J; Li X
    BMC Cancer; 2024 May; 24(1):629. PubMed ID: 38783224
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The β-arrestin1/endothelin axis bolsters ovarian fibroblast-dependent invadosome activity and cancer cell metastatic potential.
    Del Rio D; Masi I; Caprara V; Ottavi F; Albertini Petroni G; Salvati E; Trisciuoglio D; Giannitelli SM; Bagnato A; Mauri E; Spadaro F; Rosanò L
    Cell Death Dis; 2024 May; 15(5):358. PubMed ID: 38777849
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Preoperative cancer antigen-125 levels as a predictor of recurrence in early-stage endometrial cancer.
    Erturk A; Korkmaz E; Arslantas Z; Bekdemir S; Erturk NK
    Rev Assoc Med Bras (1992); 2024; 70(5):e20231115. PubMed ID: 38775501
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals.
    Li C; Cui Q; Wang X; Yao S; Tu H; Chen M
    BMC Cancer; 2024 May; 24(1):609. PubMed ID: 38769484
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Racial and Ethnic Inequities in cancer Care Continuity During the COVID-19 Pandemic Among Those With SARS-CoV-2.
    Islam JY; Hathaway CA; Hume E; Turner K; Hallanger-Johnson J; Tworoger SS; Camacho-Rivera M
    JAMA Netw Open; 2024 May; 7(5):e2412050. PubMed ID: 38767916
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Construction and Validation of a Nomogram to Predict the Postoperative Venous Thromboembolism Risk in Patients with HGSOC.
    Huang Z; Li L; Gong Z; Tang L
    Clin Appl Thromb Hemost; 2024; 30():10760296241255958. PubMed ID: 38767088
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Fertility preservation in female cancer patients in Brazil: perceptions and attitudes of infertility specialists.
    Ranniger RL; Lamaita RM; D'Abreu BF; Tolentino MR; Cândido EB; Andrade WP; Nogueira-Rodrigues A; Silva-Filho AL
    Rev Bras Ginecol Obstet; 2024; 46():. PubMed ID: 38765513
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. A Curious Case of Clear Cell Morphology in a Patient with Lung cancer: Diagnostic Challenges.
    Bonnier A; Najmuddin M; Curry MD; Nida A; Saha BK
    Prague Med Rep; 2024; 125(2):138-145. PubMed ID: 38761046
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Weighted metrics are required when evaluating the performance of prediction models in nested case-control studies.
    Rentroia-Pacheco B; Bellomo D; Lakeman IMM; Wakkee M; Hollestein LM; van Klaveren D
    BMC Med Res Methodol; 2024 May; 24(1):115. PubMed ID: 38760688
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Dual‑regulated oncolytic adenovirus carrying
    Zhao T; Ye W; Zhang R; Zhu X; Shi Q; Xu X; Chen W; Xu L; Meng Y
    Mol Med Rep; 2024 Jul; 30(1):. PubMed ID: 38757346
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.
    Li H; Peng Z; Zhu J; Zhao W; Huang Y; An R; Zheng H; Qu P; Wang L; Zhou Q; Wang D; Lou G; Wang J; Wang K; Kong B; Xie X; Yin R; Low J; Rozita AM; Sen LC; Meng YC; Kiong KS; Liu J; Liang Z; Lv W; Zhu Y; Hu W; Sun W; Su J; Wang Q; Zang R; Ma D; Gao Q
    BMC Med; 2024 May; 22(1):199. PubMed ID: 38755585
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. When to reinvite initially ineligible populations for targeted lung cancer screening?
    Goodley P; Crosbie PAJ; Sperrin M; Merchant Z; Booton R; Balata H
    BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38754907
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
    Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
    JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Small Nucleolar RNAs as Diagnostic and Prognostic Biomarkers in cancer: A Systematic Review and Meta-Analysis.
    Gao L; Fan J; He J; Che X; Wang X; Han C
    Technol Cancer Res Treat; 2024; 23():15330338241245939. PubMed ID: 38752263
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. CircAGFG1 Promotes ovarian cancer Progression Through the miR-409-3 p/ZEB1 Axis.
    Luo J; Zhong H; Guo M; Xiao P; Cao R; Zhao M; Jing Y
    Technol Cancer Res Treat; 2024; 23():15330338241252423. PubMed ID: 38752261
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors.
    Chung DC; Ghaedi M; Warner K; Sayad A; Saibil SD; Bernardini MQ; Clarke BA; Shaw PA; Butler MO; Easson A; Morrissy S; Wang BX; Nguyen L; Ohashi PS; Jacquelot N
    Oncoimmunology; 2024; 13(1):2349347. PubMed ID: 38746870
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Shikonin reduces M2 macrophage population in ovarian cancer by repressing exosome production and the exosomal galectin 3-mediated β-catenin activation.
    Wang M; Sun Y; Gu R; Tang Y; Han G; Zhao S
    J Ovarian Res; 2024 May; 17(1):101. PubMed ID: 38745186
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 1955.